The University of Kansas Cancer Center requests CCSG funds for developmental funds to be specifically used for the pilot studies program and to supplement new recruitment packages. The major purpose of the Pilot Studies Program is to provide support for highly innovative research proposals in new, exciting, and potentially breakthrough areas of cancer research. The pilot research proposal must be cancer-related and must not overlap with existing funding from any source (different focus and different aims). Ultimately, the goal is to have these funds provide critical preliminary data to test new hypotheses and assess feasibility of ideas that might allow for rapid advancement in the field and make an impact in basic, clinical, or translational research. The merit of these proposals will be assessed by members of the KUCC-Leadership Council and approved by the Director prior to funding. To actively build and improve our research environment, KUCC is committed to recruiting additional cancer researchers to increase the national and international status of the Cancer Center, enhance the number of NCI/cancer-related grants, fill critical research positions and build the four cancer research programs. Each purposeful hire aims to further the scientific vision, mission, and goals of the Cancer Center research programs. The funds requested will be used to supplement the recruitment packages of future cancer center recruits and will be leveraged by matching with Kansas Bioscience Authority funds.
The University of Kansas Cancer Center plans to utilize developmental funds to continue and to supplement its highly successful pilot project program to provide funding to test new research ideas. In addition, we will use a portion of the funds to supplement recruitment packages for new investigators.
|Walker, Logan C; Marquart, Louise; Pearson, John F et al. (2017) Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet 25:432-438|
|Lal, Shruti; Cheung, Edwin C; Zarei, Mahsa et al. (2017) CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype. Mol Cancer Res 15:696-707|
|Xiao, Lifu; Tian, Xiumei; Harihar, Sitaram et al. (2017) Gd2O3-doped silica @ Au nanoparticles for in vitro imaging cancer biomarkers using surface-enhanced Raman scattering. Spectrochim Acta A Mol Biomol Spectrosc 181:218-225|
|Pessetto, Ziyan Y; Chen, Bin; Alturkmani, Hani et al. (2017) In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. Oncotarget 8:4079-4095|
|Wolfe, Andy R; Ernlund, Amanda; McGuinness, William et al. (2017) Suppression of intestinal tumorigenesis in Apc mutant mice upon Musashi-1 deletion. J Cell Sci 130:805-813|
|Sasaki, Ken; Kurahara, Hiroshi; Young, Eric D et al. (2017) Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer. Clin Exp Metastasis 34:229-239|
|New, Jacob; Arnold, Levi; Ananth, Megha et al. (2017) Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target. Cancer Res 77:6679-6691|
|Brinker, Amanda E; Vivian, Carolyn J; Koestler, Devin C et al. (2017) Mitochondrial Haplotype Alters Mammary Cancer Tumorigenicity and Metastasis in an Oncogenic Driver-Dependent Manner. Cancer Res 77:6941-6949|
|Do, Thuy-Vy; Hirst, Jeff; Hyter, Stephen et al. (2017) Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. Oncotarget 8:50376-50392|
|Spaw, Mark; Anant, Shrikant; Thomas, Sufi Mary (2017) Stromal contributions to the carcinogenic process. Mol Carcinog 56:1199-1213|
Showing the most recent 10 out of 135 publications